Outcomes of Treatment With Paclitaxel-Coated Devices for Peripheral Arterial Disease
نویسندگان
چکیده
منابع مشابه
Local paclitaxel delivery for treatment of peripheral arterial disease.
Local drug delivery is the process by which therapeutic agents are administered to targeted segments of the circulatory system to treat vascular disease. The aims are to optimize therapeutic efficacy by direct drug administration and to minimize untoward effects associated with systemic delivery. This is accomplished in humans with drug-eluting stents (DES), drug-coated balloons (DCB), and dire...
متن کاملPercutaneous revascularization for peripheral arterial disease: paclitaxel saves the day.
Patients presenting with femoropopliteal (FP) disease often require revascularization for lifestyle-limiting claudication medical therapy that failed, or for critical limb ischemia. Percutaneous revascularization for FP disease has been fraught with challenges since the initial description of percutaneous transluminal balloon angioplasty (PTA) of the FP artery. Due to high rates of arterial dis...
متن کاملPrevalence of Peripheral Arterial Disease in Diabetic Patients
Objective: Peripheral Arterial Disease (PAD) is a state characterized by atherosclerotic occlusive disease of lower extremities. Diabetes is the main risk factor for PAD. Material and Methods: To assess the prevalence of PAD, a cross sectional study was performed on 352 diabetic patients who referred to Yazd diabetes research center from 2007 to 2010. Vascular assessment was done by measuring ...
متن کامل[Diagnosis and treatment for peripheral arterial disease].
Peripheral arterial disease (PAD) is atherosclerosis leading to narrowing of the major arteries distal to the aortic arch. The most common presenting symptom is claudication; however, only 10% of patients have classic claudication. Approximately 8 to 12 million Americans have PAD, including 15% to 20% of adults older than 70 years. The ankle-brachial index (ABI) can be used to screen for and di...
متن کاملPaclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis
Background—Treatment of in-stent restenosis with paclitaxel-coated balloon catheter as compared with plain balloon angioplasty has shown surprisingly low late lumen loss at 6 months and fewer major adverse cardiac events up to 2 years. We compared the efficacy and safety of a paclitaxel-coated balloon with a paclitaxel-eluting stent as the current standard of care. Methods and Results—One hundr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Vascular Surgery
سال: 2020
ISSN: 0741-5214
DOI: 10.1016/j.jvs.2020.04.247